Overview

NCI Definition [1]:
A bispecific T-cell engager (BiTE) antibody composed of two single-chain variable fragments (scFv), one directed against the tumor-associated antigen (TAA) human B-cell maturation antigen (BCMA; TNFRSF17), and one that is directed against the CD3 antigen found on T-lymphocytes, with potential immunostimulating and antineoplastic activities. Upon administration of anti-BCMA/CD3 T-cell engaging antibody CC-93269, this bispecific antibody binds to both CD3 on cytotoxic T-lymphocytes (CTLs) and BCMA found on BCMA-expressing tumor cells. This activates and redirects CTLs to BCMA-expressing tumor cells, which results in the CTL-mediated death of BCMA-expressing tumor cells. BCMA, a member of the tumor necrosis factor receptor superfamily that is specifically overexpressed on malignant plasma cells, plays a key role in promoting plasma cell survival.

Cc-93269 has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating cc-93269, 1 is phase 1 (1 open).

Multiple myeloma is the most common disease being investigated in cc-93269 clinical trials [2].

Drug Details

Synonyms [2]:
anti-bcma/cd3 bispecific antibody cc-93269, bcma x cd3 t cell engaging antibody cc-93269, bcma x cd3 t-cell engaging antibody cc-93269, bcma/cd3 t-cell bi-specific antibody cc-93269, bcma/cd3-directed bispecific t-cell engager antibody cc-93269, bcmaxcd3 bite antibody cc-93269, em901, cc 93269, bi-specific antibody cc-93269, bcmaxcd3 tcb cc-93269
Drug Target(s) [2]:
CD3, TNFRSF17
NCIT ID [1]:
C156052

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.